{
    "clinical_study": {
        "@rank": "75711", 
        "arm_group": [
            {
                "arm_group_label": "Super Rapid Magstim Stimulator  rTMS QP", 
                "arm_group_type": "Active Comparator", 
                "description": "rTMS QP is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "rTMS QP placebo (coil perpendicular to the scalp) is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients."
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluation of inhibiting rTMS QP over the visual cortex for the prevention of chronic\n      migraine. The aim of the study is to confirm that inhibiting rTMS QP is capable to decrease\n      the frequency of migraine and if its effect is stronger than placebo effect."
        }, 
        "brief_title": "RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Migraine", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "detailed_description": {
            "textblock": "The investigators have already inquired if inhibiting rTMS QP over the visual cortex\n      determines a reduction of frequency of migraine in a previous study. After 2 weekly sessions\n      for a month, the investigators demonstrated a reduction of 47% in migraine frequency. In\n      this study, the investigators aim to compare rTMS QP effect with the placebo effect and to\n      evaluate if rTMS QP is capable to induce changes in VEP, CHEPS and QST."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosis of chronic migraine (ICHD III beta 1.3) with or without medication overuse.\n\n        Exclusion Criteria:\n\n          -  other diseases or contraindication for the magnetic stimulation (epilepsy, pacemaker,\n             metallic prothesis)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02122744", 
            "org_study_id": "CB-1331"
        }, 
        "intervention": {
            "arm_group_label": "Super Rapid Magstim Stimulator  rTMS QP", 
            "description": "The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.\nThe side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil.", 
            "intervention_name": "Super Rapid Magstim Stimulator", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "contact": {
                "email": "roberta.baschi@gmail.com", 
                "last_name": "Roberta Baschi, MD", 
                "phone": "0032/042256925"
            }, 
            "facility": {
                "address": {
                    "city": "Li\u00e8ge", 
                    "country": "Belgium", 
                    "zip": "4000"
                }, 
                "name": "Roberta Baschi"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomised Placebo Controlled Trial of rTMS Quadri Pulse Over Visual Cortex for the Prevention of Chronic Migraine", 
        "overall_contact": {
            "email": "dmagis@chu.ulg.ac.be", 
            "last_name": "Delphine Magis, MD", 
            "phone": "0032/042257811"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Li\u00e8ge", 
                "last_name": "Jean Schoenen, HP", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Li\u00e8ge", 
                "last_name": "Delphine Magis, MD,PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Belgium: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The investigators evaluate the frequency of migraine during the treatment and 2 months after its end.", 
            "measure": "Frequency of migraine", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02122744"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital of Liege", 
            "investigator_full_name": "Jean Schoenen", 
            "investigator_title": "Honorary Full Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The investigators evaluate the intensity of migraine during the treatment and 2 months after its end", 
                "measure": "Intensity of migraine", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The investigators evaluate acute medication intake during the treatment and 2 months after its end", 
                "measure": "Acute medication intake", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The investigators evaluate attack duration during the treatment and 2 months after its end", 
                "measure": "Attack duration", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The investigators evaluate scores on psychological scales during the treatment and 2 months after its end", 
                "measure": "Scores on psychological scales", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "University Hospital of Liege", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital of Liege", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}